Condition
Adrenal Gland Pheochromocytoma
Total Trials
3
Recruiting
1
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Active Not Recruiting2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT02402244RecruitingPrimary
Project: Every Child for Younger Patients With Cancer
NCT02834013Phase 2Active Not Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT05142241Phase 2Active Not RecruitingPrimary
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
Showing all 3 trials